Hidetoshi Masumoto, MD, PhD
RIKEN Center for Biosystems Dynamics Research (BDR), Kobe, Japan
Leader for Clinical Translational Research Program, Senior Research Scientist, RIKEN Center for Biosystems Dynamics Research (BDR), Kobe, JapanAssistant Professor, Department of Cardiovascular Surgery, Kyoto University Hospital, Kyoto, Japan
Dr. Masumoto graduated and received his medical degree from Faculty of Medicine, Kyoto University. He completed his Cardiovascular Surgery Residency at Kyoto University Hospital and Kumamoto Central Hospital and joined to Shizuoka City Hospital as a staff surgeon of the Department of Cardiovascular Surgery in 2002.
Besides his clinical career, Dr. Masumoto started his research career from 2007 at the Department of Cardiovascular Surgery and Center for iPS Cell Research and Application (CiRA), Kyoto University as a doctoral course student. He received a doctorate in medicine in 2012 for the researches about cardiac regeneration based on pluripotent stem cells and cell sheet technology. In 2013, he moved to Cardiovascular Innovation Institute, University of Louisville, Kentucky, USA as a postdoctoral fellow to expand his research for the clinical translation of biomimetic artificial heart tissues including human induced pluripotent stem (iPS) cell-derived cardiovascular cell lineages. In 2015, he returned to Kyoto University as an Assistant Professor at CiRA then moved to the Department of Cardiovascular Surgery, Kyoto University Hospital in 2016. In 2017, Dr. Masumoto launched an independent research group as the Leader for Clinical Translational Research Program at RIKEN Center for Biosystems Dynamics Research (BDR), Kobe, Japan in addition with the clinical position at Kyoto University Hospital.
Dr. Masumoto’s research focuses on clinical translation of human iPS cell technology in cardiovascular medicine including cardiac regenerative therapy, disease modeling and drug discovery using bioengineered human iPS cell-derived cardiac tissues, development of the strategies for the improvement of the outcome of cardiovascular surgery using various animal disease models, and pre-clinical and clinical studies of basic fibroblast growth factor for clinical limb ischemia and ischemic heart diseases with gelatin hydrogel-based drug delivery system.